IP Library Granted Patent US 8,334,276
Granted Patent B2
US 8,334,276 · App. 13/373,226 · Granted Dec 18, 2012

Cystitis treatment with high dose chondroitin sulfate

Assignee: Stellar Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,334,276
App. No.
13/373,226
Granted
Dec 18, 2012
Kind
B2
Abstract

Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis.

Claims (3)

1. A pharmaceutical composition adapted for instillation to the bladder of a human patient afflicted with cystitis, the composition comprising a unit dose of chondroitin sulfate in an amount of 400 mgs, and an aqueous vehicle in a volume sufficient to expose the bladder surface to be treated, wherein the aqueous vehicle volume is 20 mL.

2. A pharmaceutical composition, in the form of a sterile chondroitin sulfate solution, consisting of a unit dose of 400 mgs of chondroitin sulfate and 20 mL of an aqueous vehicle.

3. A kit comprising the phamiaceutical composition of claim 2 and printed instructions teaching the administration thereof by instillation to the bladder of a subject afflicted with interstitial cystitis.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2023
From: DEERFIELD PRIVATE DESIGN FUND III, L.P., AS AGENT
To: NUVO PHARMACEUTICALS INC.; ARALEZ PHARMACEUTICALS CANADA INC.; NUVO PHARMACEUTICALS (IRELAND) DESIGNATED ACTIVITY COMPANY (F/K/A NUVO PHARMACEUTICALS (IRELAND) LIMITED)
Reel/Frame 062974/0236 →
SECURITY INTEREST Recorded Dec 31, 2018
From: NUVO PHARMACEUTICALS INC.; NUVO PHARMACEUTICALS (IRELAND) DESIGNATED ACTIVITY COMPANY; ARALEZ PHARMACEUTICALS CANADA INC.
To: DEERFIELD PRIVATE DESIGN FUND III, L.P., AS AGENT
Reel/Frame 047875/0410 →
CHANGE OF NAME Recorded Mar 7, 2018
From: TRIBUTE PHARMACEUTICALS CANADA INC.
To: ARALEZ PHARMACEUTICALS CANADA INC.
Reel/Frame 045518/0563 →
RELEASE OF SECURITY INTEREST Recorded Feb 5, 2016
From: SWK FUNDING LLC
To: TRIBUTE PHARMACEUTICALS CANADA, INC.
Reel/Frame 037674/0301 →
RELEASE OF SECURITY INTEREST Recorded Aug 27, 2013
From: MIDCAP FUNDING III, LLC
To: TRIBUTE PHARMACEUTICALS CANADA INC.
Reel/Frame 031093/0486 →
SECURITY AGREEMENT Recorded Aug 8, 2013
From: TRIBUTE PHARACEUTICALS CANADA LLC
To: SWK FUNDING LLC
Reel/Frame 030988/0171 →
CONFIRMATION OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 28275, FRAME 0357 Recorded Mar 20, 2013
From: TRIBUTE PHARMACEUTICALS CANADA INC.
To: MIDCAP FUNDING III, LLC, AS AGENT
Reel/Frame 030049/0126 →
MERGER Recorded Feb 21, 2013
From: STELLAR PHARMACEUTICALS INC.
To: TRIBUTE PHARMACEUTICALS CANADA INC.
Reel/Frame 029849/0376 →
SECURITY AGREEMENT Recorded May 25, 2012
From: STELLAR PHARMACEUTICALS INC.; TRIBUTE PHARMACEUTICALS CANADA LTD.; TRIBUTE PHARMA CANADA INC.
To: MIDCAP FUNDING III, LLC, AS AGENT
Reel/Frame 028275/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2011
From: RIEHL, PETER R.; HAHN, SUNGTACK SAMUEL
To: STELLAR INTERNATIONAL INC.
Reel/Frame 027331/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2011
From: STELLAR INTERNATIONAL INC.
To: STELLAR PHARMACEUTICALS INC.
Reel/Frame 027331/0327 →
Continuity (4)
Continuation 12804478 · Jul 21, 2010
Continuation 10546511
Continuation In Part 10367970 · Feb 19, 2003
Related Publication 20120058969A1 · Mar 8, 2012